Aptose Biosciences, Inc.

Good afternoon, my name is Chino and I will be your conference operator today. I would like to welcome everyone to the Uptoes Biosciences conference call for first quarter ended March 31st, 2021. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, please press the pound key. Thank you. As a reminder, this conference call may be recorded. I would like to introduce Ms. Susan Pietropaolo. Please go ahead.

Thank you, Chino. Good afternoon and welcome to the Aptos Biosciences Conference Call to discuss financial and operational results for the first quarter ended March 31, 2021. I am Susan Pietropalo, Communications Representative for Aptos Biosciences. Joining me on the call today are Dr. William G. Rice, Chairman, President, and CEO, Dr. Yodi Marango, Senior Vice President, Chief Financial Officer and Chief Business Officer, and Dr. Rafael Behar, Senior Vice President, Chief Medical Officer. Before we proceed, I would like to remind everyone that certain statements made during this call will include forward-looking statements within the meaning of U.S. and Canadian securities laws. Forward-looking statements reflect Aptos' current expectations regarding future events but are not guarantees of performance, and it is possible that actual results and performance could differ materially from these stated expectations. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievement to differ materially from those expressed. To learn more about these risks and uncertainties, please read the risk factors set forth in Aptos' most recent annual report on Form 10-K and SEC and CEDAR filings. All forward-looking statements made during this call speak only as of the date they are made. Aptos undertakes no obligation to revise or update the statements to reflect events or circumstances after the date of this call, except as required by law. I will now turn the call over to Dr. Rice, Chairman, President, and CEO of Aptos Biosciences. Dr. Rice?

Thank you, Susan. I'd like to welcome everyone to our call.